Lantheus Holdings announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for LNTH-2501, an imaging agent used to detect somatostatin receptor–positive neuroendocrine tumors (NETs). The decision deadline has been extended 3 months, shifting from March 29 to the new date of June 29, 2026.

According to the company, the extension was requested by the FDA to allow additional time for review of manufacturing-related information submitted as part of the application. Importantly, Lantheus emphasized that the delay is not related to concerns about the product’s safety or clinical efficacy, which remain unchanged.

LNTH-2501 is a diagnostic radiopharmaceutical kit designed to support PET imaging. Specifically, it enables the preparation of gallium-68 edotreotide, an imaging agent used to detect somatostatin receptor–positive NETs. These tumors are relatively rare and often slow-growing cancers that can develop in hormone-producing cells throughout the body, most commonly in the gastrointestinal tract, pancreas, and lungs.

The imaging agent aims to improve detection and localization of NETs in both adult and pediatric patients. By enhancing visualization of tumors, LNTH-2501 has the potential to support more accurate diagnosis, staging, and treatment planning. This includes helping clinicians determine eligibility for targeted therapies such as peptide receptor radionuclide therapy (PRRT), as well as guiding surgical decision-making.

LNTH-2501 is designed as a two-vial kit that allows radiopharmacies to prepare the final imaging agent on-site by combining the components with gallium-68 sourced from a generator. This approach is intended to increase flexibility and accessibility, enabling more healthcare facilities to produce the tracer as needed rather than relying on centralized manufacturing and distribution.

Data Supporting the FDA Application

The NDA was submitted under the FDA's 505(b)(2) regulatory pathway, which permits reliance on existing published clinical evidence. The submission is anchored by two prospective trials evaluating the diagnostic accuracy of gallium-68 edotreotide PET/CT vs standard-of-care Octreoscan SPECT imaging.

The first trial (NCT01619865) enrolled 177 patients with known or suspected SSTR-positive NETs.² Gallium-68 edotreotide PET/CT was compared against Octreoscan SPECT combined with high-resolution, contrast-enhanced CT. Results demonstrated positive diagnostic agreement rates of 91% (95% CI, 85%-95%) and 90% (95% CI, 84%-95%) for Readers 1 and 2, respectively, with negative agreement rates of 89% (95% CI, 75%-96%) and 86% (95% CI, 73%-95%).²

A second prospective trial (NCT01869725) compared gallium-68 edotreotide PET/CT against indium-111 pentetreotide combined with contrast-enhanced CT or MRI.³ Reader 1 demonstrated positive and negative agreement rates of 92% and 75%, respectively, while Reader 2 showed agreement rates of 90% and 75%.³ Across both studies, gallium-68 edotreotide consistently met or exceeded the performance of conventional SPECT-based imaging, and these findings have not been questioned as part of the current review.

Going Forward

Despite the regulatory delay, analysts and company stakeholders have responded with cautious optimism. Because the extension is tied to manufacturing review rather than clinical performance, it is not expected to materially impact the perceived effectiveness or safety profile of the product. Some analysts noted relief that the review did not raise concerns about trial data, which could have posed a more significant setback.

If approved, LNTH-2501 would expand Lantheus’ portfolio of diagnostic imaging agents and further strengthen its presence in oncology-focused radiopharmaceuticals. The company has been actively advancing its pipeline to address unmet needs in cancer detection and monitoring, with a particular focus on improving access to high-quality imaging tools.

Looking ahead, Lantheus anticipates a potential commercial launch later in 2026, pending FDA approval. The three-month extension is expected to shift timelines slightly but does not alter the overall development trajectory for the product.

REFERENCES

1. Lantheus announces three-month extension of PDUFA date for LNTH-2501 (Ga 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). News release. Lantheus Holdings, Inc. March 17, 2026. Accessed March 20, 2026. https://tinyurl.com/596vnanf

2. Deppen SA, Blume J, Bobbey AJ, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57(6):872-878. doi:10.2967/jnumed.115.165803

3. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56(1):40-47. doi:10.1111/j.1754-9485.2011.02327.x